
SCIO-469
CAS No. 309913-83-5
SCIO-469 ( Talmapimod | SCIO469 | SCIO 469 )
产品货号. M13991 CAS No. 309913-83-5
一种有效的选择性 p38α MAPK 抑制剂,IC50 为 9 nM。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
2MG | ¥567 | 有现货 |
![]() ![]() |
5MG | ¥948 | 有现货 |
![]() ![]() |
10MG | ¥1515 | 有现货 |
![]() ![]() |
25MG | ¥3216 | 有现货 |
![]() ![]() |
50MG | ¥4771 | 有现货 |
![]() ![]() |
100MG | ¥6828 | 有现货 |
![]() ![]() |
200MG | 获取报价 | 有现货 |
![]() ![]() |
500MG | 获取报价 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称SCIO-469
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述一种有效的选择性 p38α MAPK 抑制剂,IC50 为 9 nM。
-
产品描述A potent, selective p38α MAPK inhibitor with IC50 of 9 nM; displays 10-fold selectivity for p38α over p38β, >2,000-fold selectivity over a panel of 20 other kinases, including other MAP kinases; decreases apoptosis in MDS CD34+ progenitors and leads to dose-dependant increases in erythroid and myeloid colony formation; enhances the ability of MG132 and bortezomib to induce the apoptosis of MM cells, and inhibits tumor growth in vivo.Rheumatoid Arthritis Phase 2 Discontinued.
-
体外实验Talmapimod (SCIO-469) (100-200 nM; 1 hour) inhibits phosphorylation of p38 MAPK in MM cells.Talmapimod inhibits LPS-induced TNF-a production in human whole blood.Talmapimod decreases constitutive p38alpha MAPK phosphorylation of both 5T2MM and 5T33MM cells.Western Blot Analysis Cell Line:MM.1S, U266, RPMI8226, MM.1R, and RPMI-Dox40 cell lines Concentration:100, 200 nM Incubation Time:1 hour Result:Strongly inhibits phosphorylation of p38 MAPK.
-
体内实验Targeting p38α MAPK with Talmapimod (SCIO-469) decreases myeloma burden in addition to preventing the development of myeloma bone disease.Talmapimod inhibits multiple myeloma growth and prevents bone disease in the 5T2MM and 5T33MM models.Talmapimod (10-90 mg/kg; p.o.; twice daily orally for 14 days) dose-dependently reduced tumor growth and also dose-dependently reduced weight of the palpable tumors at termination. Animal Model:Six-week-old male triple immune-deficient BNX mice (RPMI-8226 MM palpable tumors)Dosage:P.o.; twice daily orally for 14 days Administration:10, 30, 90 mg/kg Result:Dose-dependently reduced tumor growth.
-
同义词Talmapimod | SCIO469 | SCIO 469
-
通路MAPK/ERK Signaling
-
靶点p38 MAPK
-
受体p38 MAPK
-
研究领域Inflammation/Immunology
-
适应症Rheumatoid Arthritis
化学信息
-
CAS Number309913-83-5
-
分子量513.0035
-
分子式C27H30ClFN4O3
-
纯度>98% (HPLC)
-
溶解度10 mM in DMSO
-
SMILESCC1CN(C(CN1C(=O)C2=C(C=C3C(=C2)C(=CN3C)C(=O)C(=O)N(C)C)Cl)C)CC4=CC=C(C=C4)F
-
化学全称1H-Indole-3-acetamide, 6-chloro-5-[[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-N,N,1-trimethyl-α-oxo-
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Navas TA, et al. Leukemia. 2006 Jun;20(6):1017-27.
2. Navas TA, et al. Blood. 2006 Dec 15;108(13):4170-7.
3. Hideshima T, et al. Oncogene. 2004 Nov 18;23(54):8766-76.
产品手册




关联产品
-
Rosin
松香是一种天然产品,可能具有治疗炎症的潜力。
-
LY2228820 dimesylate
LY2228820 dimesylate (Ralimetinib) 是一种有效的、选择性的、口服的 p38 MAPK 抑制剂,对 p38α 和 p38β 的 IC50 分别为 5.3 和 3.2 nM。
-
MW181 hydrochloride
MW181 (MW01-10-181SRM) 是一种异构体选择性、脑渗透性、口服生物可利用的 p38α MAPK 小分子抑制剂,Ki 为 184 nM。